Ekso Bionics Holdings, Inc. (EKSO) Shares Up 25.1%
Shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) shot up 25.1% during mid-day trading on Monday . The company traded as high as $2.45 and last traded at $2.39. 9,402,000 shares were traded during mid-day trading, an increase of 1,293% from the average session volume of 675,060 shares. The stock had previously closed at $1.91.
A number of research firms have recently issued reports on EKSO. Zacks Investment Research raised shares of Ekso Bionics Holdings from a “hold” rating to a “buy” rating and set a $1.50 price target for the company in a research report on Friday, September 15th. ValuEngine raised shares of Ekso Bionics Holdings from a “strong sell” rating to a “sell” rating in a research report on Friday.
The company has a quick ratio of 5.73, a current ratio of 6.09 and a debt-to-equity ratio of 0.18.
Ekso Bionics Holdings (NASDAQ:EKSO) last issued its quarterly earnings data on Wednesday, November 8th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.05). The business had revenue of $1.60 million for the quarter, compared to the consensus estimate of $2.40 million. Ekso Bionics Holdings had a negative net margin of 343.53% and a negative return on equity of 323.00%. equities research analysts forecast that Ekso Bionics Holdings, Inc. will post -0.81 earnings per share for the current year.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. National Planning Corp raised its position in Ekso Bionics Holdings by 122.2% during the third quarter. National Planning Corp now owns 520,942 shares of the company’s stock valued at $620,000 after acquiring an additional 286,492 shares in the last quarter. Carl Domino Inc raised its position in Ekso Bionics Holdings by 125.2% during the third quarter. Carl Domino Inc now owns 184,788 shares of the company’s stock valued at $224,000 after acquiring an additional 102,734 shares in the last quarter. Intellectus Partners LLC raised its position in Ekso Bionics Holdings by 5.3% during the second quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock valued at $244,000 after acquiring an additional 5,294 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in Ekso Bionics Holdings by 32.9% during the second quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock valued at $1,650,000 after acquiring an additional 176,197 shares in the last quarter. 2.87% of the stock is currently owned by hedge funds and other institutional investors.
About Ekso Bionics Holdings
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
Receive News & Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.